-
Astellas Pharma introduces Astagraf XL for kidney-transplant patients
NORTHBROOK, Ill. — Astellas Pharma has introduced a new drug for preventing the body from rejecting transplanted organs, the company said Thursday.
The drug maker announced the availability of Astagraf XL (tacrolimus) extended-release capsules in pharmacies. The drug is designed for use in kidney transplant patients with Genenetech's CellCept (mycophenolate mofetil) and corticosteroids, with or without induction of Novartis' Simulect (basiliximab).